A recent study revealed that both therapies had shown benefits in the treatment of fibromyalgia. The combination of pregabalin and milnacipran is not much effective than monotherapy of pregabalin in the treatment of fibromyalgia.

This randomized open study aimed to compare the efficacy of combined pregabalin and milnacipran therapy and, pregabalin as a monotherapy. It was performed on 58 female patients who were suffering from fibromyalgia.

Participants were randomly allocated to receive either 150 mg pregabalin monotherapy twice daily (Group 1) or combined pregabalin (150 mg twice daily) and milnacipran  (50 mg twice daily) for three months.  The FM impact questionnaire (FIQ), visual analog scale (VAS) and Leeds Sleep Evaluation Questionnaire were the endpoints estimated after three months.

Statistically, a major improvement was observed in FIQ and VAS scores in both groups, as shown in the following table:

The following figure shows the percentage of pain improvement in both the groups:

However, there is no notable revelation to prove the better efficiency of combined therapy.

Thus, it is concluded that the pregabalin alone and as combined therapy with milnacipran has shown enough efficacy. However, the combined therapy has not revealed any superiority in the treatment of fibromyalgia over the monotherapy.